Real‐life experience on effectiveness and tolerability of topical ivermectin in papulopustular rosacea and antiparasitic effect on Demodex mites

• DOI: 10.1111/dth.13093
• Publication Date: 2019-10-03T09:32:07Z
• Authors: Ilaria Trave; Giulia Merlo; Emanuele Cozzani; Aurora Parodi
• Keywords: Tolerability; Papulopustular; Demodicosis

Ivermectin is a drug approved for the treatment of papulopustular rosacea (PPR). Although clinical guidelines recommend use ivermectin as first-line in patients with almost clear and mild rosacea, studies concerning its on them are lacking. This study investigated effectiveness tolerability to severe assessed antiparasitic effect Demodex mites. retrospective based 50 affected by PPR treated topical 1% once daily over 16 weeks. The disease severity, patient-examined improvement, safety assessment were evaluated. mites studied standardized skin surface biopsy. all severity achieved therapeutic success. number inflammatory lesions was significantly decreased (p < .0001), mild, moderate, .001) forms. A complete remission = .005) 82% none-to-mild cutaneous adverse events. Thirty-two percent positive mites, turned negative after an effective not only moderate but also clear/mild rosacea.